Medical devices, healthcare technology and the business of care
PMA approval · P220014

CraniSeal Dural Sealant

Pramand, LLC · Decision date Jul 6, 2023

MEDTECHLEDGER EXPLANATIONP220014

What did the FDA approve?

FDA approved the CraniSeal Dural Sealant from Pramand, LLC on July 6, 2023. The device is indicated for patients 18 years of age and older as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.

The approval is an original PMA under product code NQR in the dural sealant category. The source statement reports the intended use but does not include clinical data, safety findings, or effectiveness endpoints. No supplement type or reason is listed, so no relationship to a prior PMA is established.

FDA approval order statement

Approval for the CraniSeal Dural Sealant. The device is indicated for use in patients >= 18 years of age as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.
Regulatory pathway
Original PMA
Clinical specialty
Neurology
Decision date
Jul 6, 2023

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P220014
Regulatory pathway
Premarket approval application
Applicant
Pramand, LLC
Product code
NQR
Decision code
APPR
Decision date
Jul 6, 2023
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Applicant
Pramand, LLC
Product code
NQR
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P220014 received

    Application receipt date recorded by FDA.

  2. P220014 · FDA decision

    APPR

  3. P220014/S013 · Related supplement

    CraniSeal Dural Sealant

Timeline entries are records held by MedtechLedger for P220014. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220014

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementOct 1, 2026FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementSep 11, 2026FDA
Pramand, LLCPMA approvalFeb 14, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pramand, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., Suite 210, Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records